Recital 5, Regulation (EU) 2022/256

In forcesince 22 Feb 2022

The EU common list includes CE-marked rapid antigen tests that are in use and have been validated in at least one Member State, and the clinical performance of which was measured based on samples collected from nasal, oropharyngeal or nasopharyngeal specimens. In July 2021, the technical working group agreed to exclude from the list rapid antigen tests that are solely based on other sampling materials, such as saliva, sputum, blood or faeces. Furthermore, the list of antigen tests neither includes pooled rapid antigen tests nor rapid antigen self-tests. The list only includes rapid antigen tests conducted by trained healthcare personnel or, where appropriate, trained operators, further increasing the likely consistency of the performance of the tests included in the list.